碘复合物治疗轻中度症状SARS-CoV-2感染患者的临床疗效:一项随机对照试验的研究方案
本研究为安慰剂对照、附加治疗、随机、平行组、多中心、优效性试验,在巴基斯坦拉合尔开展,纳入轻中度症状COVID-19患者,按1:1:1:1随机分为四组(每组50例):A组口服胶囊、B组口服混悬糖浆、C组咽喉喷雾,均给予含200 mg元素碘的离子碘聚合物复合物,X组为标准治疗加安慰剂;通过RT-PCR和高分辨率CT监测,评估病毒载量清除、症状缓解时间、死亡获益等。
要点
- 试验比较离子碘聚合物复合物三种剂型(胶囊、糖浆、咽喉喷雾)附加标准治疗与安慰剂附加标准治疗的疗效。
- 主要评估指标包括病毒载量清除、症状缓解时间、临床与影像学改善、死亡率及住院情况。
- 研究采用封闭标签、适应性设计并允许样本量重新评估,计划每组50例轻中度症状患者。
核心结论
- 研究旨在评估碘复合物作为附加治疗对轻中度症状COVID-19患者的优效性,假设其可快速降低病毒载量、改善临床与影像学表现、降低死亡率并减少住院。
研究设计与样本
- 安慰剂对照、附加治疗、随机、平行组、封闭标签、适应性(允许样本量重新评估)、多中心、优效性框架试验,1:1:1:1分配。
- 在巴基斯坦拉合尔的Shaikh Zayed Post-Graduate Medical Complex、Ali Clinic和Doctors Lounge开展。
- 纳入轻中度症状COVID-19患者,每组50例,共四组:A组离子碘聚合物复合物胶囊、B组混悬糖浆、C组咽喉喷雾、X组标准治疗加安慰剂,三种剂型均含200 mg元素碘。
主要发现
- 原文为研究方案,未报告结果数据。
- 数据通过自建封闭式问卷在获得书面知情同意后收集,使用SAS 9.4分析。
- 患者通过RT-PCR和高分辨率CT胸部监测,并分析症状持续时间及死亡获益。
关键数值与推荐
- 干预制剂为离子碘聚合物复合物,含200 mg元素碘。
- 分组为A组胶囊、B组混悬糖浆、C组咽喉喷雾、X组标准治疗加安慰剂,每组50例。
- 主要评估包括病毒载量清除、症状缓解时间、临床与放射学改善、死亡率及住院情况。
临床怎么用
- 原文为研究方案,未给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus-infected millions globally. Despite a wide range of advised options for the treatment of COVID-19, a single strategy to tackle this pandemic remains elusive, thus far. That is why we are conducting a clinical trial to find out the efficacy of iodine complex to clear a viral load of severe respiratory syndrome coronavirus-2 (SARS-CoV-2) along with a reduction in time taken to alleviate symptoms. METHOD: The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a closed-label and adaptive with sample size reassessment, multi-centered design with a 1:1:1:1 allocation ratio and superiority framework. It will be conducted in Shaikh Zayed Post-Graduate Medical Complex, Ali Clinic, and Doctors Lounge, Lahore, Pakistan. This study will have three arms of mild to moderately symptomatic COVID-19 patients (50 patients in each) which will receive ionic-iodine polymer complex with 200 mg of elemental iodine: interventional arm A will have encapsulated, arm B will receive suspension syrup form, arm C will get throat spray, while arm X will be standard care with placebo. Data will be collected on self-constructed, close-ended questionnaires after obtaining written consent. Data will be analyzed using SAS version 9.4. COVID-19 patients will be monitored by RT-PCR and HRCT (high-resolution computed tomography) chest. In addition to these, the duration of the symptomatic phase and mortality benefits will be analyzed in both groups. DISCUSSION: The study is designed to measure the superior efficacy of the iodine complex as an add-on in treating COVID-19-positive patients with mild to moderate symptoms. This combination is hypothesized to improve various parameters like rapid viral load reduction, clinical and radiological improvement, lower mortality, and reduction in hospitalization. The trial will aid in devising a better strategy to cope with COVID-19 in a relatively inexpensive and accessible way. The implications are global, and this could prove itself to be the most manageable intervention against COVID-19 especially for patients from limited-resource countries with deprived socioeconomic status. TRIAL REGISTRATION: ClinicalTrials.gov NCT04473261 . Registered on July 16, 2020.
引用
- Ashraf S, Ashraf S, Ashraf M, et al. Clinical efficacy of iodine complex in SARS-CoV-2-infected patients with mild to moderate symptoms: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35045888. doi:10.1186/s13063-021-05848-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。